代谢驱动因素和心力衰竭的救援者
Rachel C Weiss1, Thiago N Menezes1, Kyle S McCommis1
1Edward A. Doisy Department of Biochemistry & Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri.
Missouri medicine
|October 16, 2023
概括
心脏缩和心力衰竭的代谢变化是有害的. 针对这些代谢变化的疗法可以显著改善心脏功能并减少心脏重塑.
科学领域:
- 心脏病学 心脏病学
- 代谢研究的研究.
- 分子生物学分子生物学
背景情况:
- 心脏缩和心力衰竭与显著的代谢失调有关.
- 人和小鼠的遗传研究表明,代谢变化有助于心脏功能障碍.
研究的目的:
- 审查心脏缩和心力衰竭中的代谢变化.
- 讨论针对这些代谢变化的治疗策略.
主要方法:
- 对疾病模型中的心脏代谢现有文献的综述.
- 基因研究的分析及其对代谢途径的影响.
- 对饮食和药理干预措施的评估.
主要成果:
- 心脏缩和失败中的代谢变化在很大程度上是不适应性的.
- 这些代谢变化有助于心脏重塑和功能受损.
- 有针对性的疗法在改善心力衰竭结果方面表现有前途.
结论:
- 了解代谢变化对于开发有效的心力衰竭治疗至关重要.
- 针对新陈代谢的饮食和药物干预可以改善心脏功能障碍.
相关概念视频
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400


